Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Silexion Therapeutics (NASDAQ: SLXN) has announced its collaboration with Evonik for developing an advanced siRNA formulation for cancer treatment. The partnership focuses on creating a long-acting siRNA PLGA microparticle formulation for SIL-204, Silexion's next-generation siRNA candidate.
The formulation, utilizing Evonik's proprietary biodegradable RESOMER® technology, has shown high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. The collaboration aims to enhance cancer treatment through sustained-release RNAi therapy, specifically targeting KRAS mutations, a significant challenge in oncology.
Silexion Therapeutics (NASDAQ: SLXN) ha annunciato la sua collaborazione con Evonik per lo sviluppo di una formulazione avanzata di siRNA per il trattamento del cancro. Il partenariato si concentra sulla creazione di una formulazione di microparticelle PLGA a rilascio prolungato di siRNA per SIL-204, il candidato di siRNA di nuova generazione di Silexion.
La formulazione, che utilizza la tecnologia biodegradabile proprietaria RESOMER® di Evonik, ha mostrato alta efficacia in modelli preclinici utilizzando topi con linee cellulari tumorali pancreatiche umane portatrici di varie mutazioni KRAS. La collaborazione mira a migliorare il trattamento del cancro attraverso una terapia RNAi a rilascio sostenuto, specificamente rivolta alle mutazioni KRAS, una sfida significativa in oncologia.
Silexion Therapeutics (NASDAQ: SLXN) ha anunciado su colaboración con Evonik para desarrollar una formulación avanzada de siRNA para el tratamiento del cáncer. La asociación se centra en crear una formulación de micropartículas PLGA de siRNA de acción prolongada para SIL-204, el candidato de siRNA de nueva generación de Silexion.
La formulación, que utiliza la tecnología biodegradable patentada RESOMER® de Evonik, ha demostrado alta eficacia en modelos preclínicos utilizando ratones con líneas celulares tumorales pancreáticas humanas que presentan diversas mutaciones de KRAS. La colaboración tiene como objetivo mejorar el tratamiento del cáncer a través de una terapia de RNAi de liberación sostenida, específicamente dirigida a las mutaciones de KRAS, un desafío significativo en oncología.
사일렉시온 테라퓨틱스 (NASDAQ: SLXN)는 암 치료를 위한 고급 siRNA 제형 개발을 위해 에보닉과 협력한다고 발표했습니다. 이 파트너십은 사일렉시온의 차세대 siRNA 후보인 SIL-204를 위한 장기 작용 siRNA PLGA 미세입자 제형의 생성에 중점을 두고 있습니다.
이 제형은 에보닉의 독점 생분해성 RESOMER® 기술을 활용하며 전임상 모델에서 높은 효능을 보여주었습니다, 인간 췌장 종양 세포주에 다양한 KRAS 변이를 가진 쥐를 사용하였습니다. 이 협력은 KRAS 변이를 표적으로 하는 지속 방출 RNAi 치료를 통해 암 치료를 개선하는 것을 목표로 합니다. 이는 온콜로지에서 중요한 도전 과제입니다.
Silexion Therapeutics (NASDAQ: SLXN) a annoncé sa collaboration avec Evonik pour développer une formulation avancée de siRNA pour le traitement du cancer. Ce partenariat se concentre sur la création d'une formulation de microparticules PLGA de siRNA à libération prolongée pour SIL-204, le candidat siRNA de nouvelle génération de Silexion.
La formulation, qui utilise la technologie biodégradable RESOMER® propriétaire d'Evonik, a montré une efficacité élevée dans des modèles précliniques utilisant des souris avec des lignées cellulaires tumorales pancréatiques humaines présentant diverses mutations KRAS. La collaboration vise à améliorer le traitement du cancer grâce à une thérapie RNAi à libération prolongée, ciblant spécifiquement les mutations KRAS, un défi significatif en oncologie.
Silexion Therapeutics (NASDAQ: SLXN) hat seine Zusammenarbeit mit Evonik zur Entwicklung einer fortschrittlichen siRNA-Formulierung für die Krebsbehandlung angekündigt. Die Partnerschaft konzentriert sich auf die Erstellung einer langwirksamen siRNA-PLGA-Mikropartikel-Formulierung für SIL-204, dem SIleXion-Kandidaten der nächsten Generation.
Die Formulierung, die die proprietäre biologisch abbaubare RESOMER®-Technologie von Evonik nutzt, hat hohe Wirksamkeit in präklinischen Modellen gezeigt, bei denen Mäuse mit menschlichen Bauchspeicheldrüsen-Tumorzelllinien verwendet wurden, die verschiedene KRAS-Mutationen tragen. Die Zusammenarbeit zielt darauf ab, die Krebsbehandlung durch eine anhaltende RNAi-Therapie zu verbessern, die speziell auf KRAS-Mutationen abzielt, eine bedeutende Herausforderung in der Onkologie.
- Successful preclinical results showing high efficacy in KRAS-mutated cancer models
- Strategic partnership with Evonik, a global leader in specialty chemicals
- Development of sustained-release formulation enhancing drug stability and targeting
- None.
Insights
This collaboration marks a significant advancement in siRNA delivery technology for cancer treatment. The use of PLGA microparticle formulation addresses one of the key challenges in RNAi therapeutics - achieving sustained drug release and improved targeting. Preclinical success in pancreatic tumor models with KRAS mutations is particularly noteworthy, as KRAS has been historically considered "undruggable." The sustained-release mechanism could potentially reduce dosing frequency while maintaining therapeutic levels, a important advantage in cancer treatment.
The partnership combines Silexion's RNAi expertise with Evonik's RESOMER® technology, potentially creating a more effective delivery system for targeting KRAS mutations. This could represent a meaningful step forward in addressing treatment resistance and improving patient outcomes in KRAS-mutated cancers, particularly pancreatic cancer which has treatment options.
The strategic collaboration with Evonik significantly enhances Silexion's competitive position in the RNAi therapeutics space. PLGA-based delivery systems have shown commercial success in other therapeutic areas and their application to siRNA delivery could provide Silexion with a significant technological edge. The positive preclinical data suggests potential for improved efficacy compared to conventional delivery methods, which could accelerate the pathway to clinical trials and eventual commercialization.
This development could strengthen Silexion's intellectual property portfolio and market position in the competitive KRAS-targeting therapeutic landscape. The sustained-release formulation could also provide a significant commercial advantage by potentially reducing treatment frequency and improving patient compliance.
Silexion is collaborating with Evonik on the development of a long-acting siRNA PLGA microparticle formulation, which has demonstrated high efficacy in preclinical models for KRAS-mutated cancers
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today revealed its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy.
Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA (RESOMER®) microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By leveraging Evonik’s formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations—one of the most challenging genetic drivers in oncology.
“We are pleased to share the details of our collaboration with Evonik Corporation, which has led to this advanced delivery system for SIL-204,” said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. “Through this ongoing collaboration, we’ve leveraged Evonik’s expertise to create a sustained-release formulation that enhances the stability and targeting of SIL-204, as part of our commitment to advancing RNAi therapies for KRAS-driven cancers.”
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion’s business strategy, ongoing preclinical studies, and collaboration with Evonik Corporation, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may," "should," "could," "might," "plan," "possible," "project," "strive," "budget," "forecast," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "potential," or "continue," or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to successfully complete preclinical studies; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding the continuation or outcome of partnerships or other relationships with third parties, including Evonik Corporation; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
CONTACT:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
FAQ
What are the preclinical results of Silexion's (SLXN) SIL-204 formulation?
How does the Evonik collaboration benefit Silexion's (SLXN) drug delivery system?
What is the target market for Silexion's (SLXN) SIL-204 therapy?
What technology is being used in Silexion's (SLXN) SIL-204 development?
